A Phase 1 Study of XmAb5574 to Evaluate the Safety, Tolerability, and Pharmacokinetics in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia

Trial Profile

A Phase 1 Study of XmAb5574 to Evaluate the Safety, Tolerability, and Pharmacokinetics in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia

Completed
Phase of Trial: Phase I/II

Latest Information Update: 25 Mar 2015

At a glance

  • Drugs MOR 208 (Primary)
  • Indications Chronic lymphocytic leukaemia
  • Focus Adverse reactions; First in man
  • Sponsors Xencor
  • Most Recent Events

    • 25 Mar 2015 According to a MorphoSys media release, results from this trial were presented at the Annual Meeting of the American Society of Hematology.
    • 07 Dec 2014 Final results published in a MorphoSys Media Release.
    • 07 Oct 2013 Status changed from active, no longer recruiting to completed, according to a MorphoSys media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top